Theravance Biopharma (TBPH) Research & Development (2013 - 2026)

Theravance Biopharma (TBPH) has reported Research & Development for 14 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 49.1% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $31.8 million (down 20.77% YoY), while the FY2025 annual figure was $37.4 million, down 0.61% from the prior year.
• Research & Development fell to $5.8 million in Q1 2026 per TBPH's latest filing, from $7.4 million in the prior quarter.
• Across five years, Research & Development topped out at $23.3 million in Q1 2022 and bottomed at $5.8 million in Q1 2026.
• Historically, Research & Development has averaged $10.9 million across 5 years, with a median of $9.5 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development tumbled 77.44% — and 2025, when it gained 27.7%.
• Theravance Biopharma's Research & Development stood at $15.3 million in 2022, then sank by 45.84% to $8.3 million in 2023, then advanced by 13.71% to $9.5 million in 2024, then decreased by 22.14% to $7.4 million in 2025, then slipped by 20.8% to $5.8 million in 2026.
• Business Quant data shows TBPH's Research & Development at $5.8 million in Q1 2026, $7.4 million in Q4 2025, and $8.1 million in Q3 2025.